EGFR Biomarkers
News and reporting on EGFR biomarkers.
The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
Kairos Pharma, PreCheck Health Services to Develop CDx for Prostate, Lung Cancer Drug
PreCheck will help the biopharma firm confirm and validate biomarkers previously identified in early-phase trials for companion diagnostic use.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.
Nanopore Sequencing-Based Method Provides Copy Number Analysis for Brain Tumors in Under Two Hours
Premium
Developed by Dartmouth researchers, the method can be performed in under two hours, offering the potential to classify a tumor in the course of surgery.